RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, has entered into a binding agreement with a single healthcare-dedicated U.S. institutional investor to purchase in a private placement Relief shares of CHF 10m, to be delivered from Relief's treasury shares that were issued out of its authorized share capital under exclusion of the existing shareholders' pre-emptive rights. The transaction closed on 18 March 2021.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. VISCHER advised Relief regarding the Swiss legal aspects of this transaction with Akerman LLP advising on U.S. laws. The VISCHER team led by partner Dr. Robert Bernet (Corporate/M&A) comprised Dr. Peter Kühn (Counsel, Corporate/M&A) and Christian Schneiter (Associate, Banking & Finance).